Locally advanced nasopharyngeal cancer

Area of Science:

• Oncology
• Head and Neck Cancer Research
• Clinical Trials

Background:

• Locally advanced squamous cell carcinomas of the nasopharynx (NPC) present a significant treatment challenge.
• The Head and Neck Cancer Intergroup phase III clinical trial (Int 0099) investigated novel treatment strategies for advanced NPC.

Purpose of the Study:

• To evaluate the efficacy of concurrent chemoradiation followed by combination chemotherapy compared to conventional radiation therapy for locally advanced NPC.
• To establish a new standard of care for patients with untreated, locally advanced stages III and IV NPC.

Main Methods:

• Phase III randomized clinical trial (Int 0099) involving patients with locally advanced NPC.
• Patients were randomized to receive either conventional radiation or radiation with concurrent chemotherapy, followed by three courses of combination chemotherapy.
• Progression-free survival (PFS) and overall survival (OS) were primary endpoints.

Main Results:

• The experimental group (chemoradiation) showed a 3-year PFS of 69% versus 24% for the control group (P < 0.001).
• The 3-year OS was 76% for the experimental group compared to 46% for the control group (P < 0.001).
• Chemoradiation significantly improved local control (41% vs 14%) and reduced distant metastases (35% vs 13%).

Conclusions:

• Concurrent chemoradiation followed by chemotherapy represents a new standard of care for locally advanced NPC, offering substantial survival benefits.
• The study highlights the effectiveness of combined modality treatment in improving outcomes for this patient population.
• Further trials are needed to determine if these results apply to the more common Asian variants of advanced NPC.